Orchid Pharma Limited reported earnings results for the second quarter and six months ended September 30, 2022. For the second quarter, the company reported sales was INR 1,652.5 million compared to INR 1,277.36 million a year ago. Revenue was INR 1,710.89 million compared to INR 1,295.03 million a year ago. Net loss was INR 53.95 million compared to net income of INR 494.02 million a year ago. Basic loss per share from continuing operations was INR 1.32 compared to INR 4.14 a year ago. Diluted loss per share from continuing operations was INR 1.32 compared to INR 4.14 a year ago. Basic loss per share was INR 1.32 compared to basic earnings per share of INR 12.1 a year ago. Diluted loss per share was INR 1.32 compared to diluted earnings per share of INR 12.1 a year ago.
For the six months, sales was INR 2,962.37 million compared to INR 2,200.49 million a year ago. Revenue was INR 3,050.08 million compared to INR 2,249.39 million a year ago. Net loss was INR 204.08 million compared to net income of INR 184.98 million a year ago. Basic loss per share from continuing operations was INR 5 compared to INR 11.07 a year ago. Diluted loss per share from continuing operations was INR 5 compared to INR 11.07 a year ago. Basic loss per share was INR 5 compared to basic earnings per share of INR 4.53 a year ago. Diluted loss per share was INR 5 compared to diluted earnings per share of INR 4.53 a year ago.